Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
Prohibited at all times as a PPAR-delta agonist under 2026 S4.4.1; non-Specified. Named explicitly in the future 2027 List. [1] [2] [3]
S4.4.1 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Medical context
Seladelpar is a PPAR-delta agonist. The January 2026 US Livdelzi label covers primary biliary cholangitis in adults, with ursodeoxycholic acid after inadequate response or alone when that treatment is intolerable. Accelerated approval was based on a laboratory marker; improved survival or prevention of liver decompensation had not been demonstrated. [4]
- US label context; the approval basis must not be restated as a proven survival benefit.
Selected warnings
The label addresses fractures, liver-test abnormalities and biliary obstruction, and does not recommend use in decompensated cirrhosis. An authorized liver-disease medicine remains subject to the applicable anti-doping rules. [4]
- Not an exhaustive warning or interaction list, and not a class-wide risk estimate for every PPAR agonist.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · Relevant official full-text sections opened
Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable
- WADA 2027 Prohibited List November revision ↗Accessed 2026-11-10 · Relevant official full-text sections opened · FUTURE 2027 SOURCE
Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable
- UKAD 2027 Prohibited List: Summary of Changes ↗Accessed 2026-11-10 · Relevant document text opened · FUTURE 2027 SOURCE
Relevant cited sections
- FDA LIVDELZI prescribing information ↗Accessed 2026-11-10 · Relevant document text opened
Relevant cited sections
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.